Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: J Cardiol. 2016 Nov 23;69(6):868–876. doi: 10.1016/j.jjcc.2016.08.010

Figure 1.

Figure 1

Kaplan-Meier estimates of endpoint-free survival during follow-up for dabigatran and warfarin users. Left panels show new users of dabigatran versus new users of warfarin. Right panels show switchers to dabigatran versus persistent warfarin users. (A) Intracranial bleeding. (B) Ischemic stroke. (C) Myocardial infarction. (D) Gastrointestinal bleeding.